A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions

Trial Profile

A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloid polyneuropathy; Cardiomyopathies
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Aug 2016 Status changed from recruiting to completed.
    • 13 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
    • 13 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top